Danaher Corporation (NYSE: DHR) shares jumped about 8% in intra-day trading on Tuesday after the life sciences company reported third-quarter results that surpassed analyst expectations, although its full-year earnings guidance landed marginally below consensus at the midpoint.
The company posted earnings per share of $1.89, beating the analyst estimate of $1.72. Revenue rose to $6.05 billion, slightly ahead of the $6 billion consensus forecast.
For fiscal 2025, Danaher projected earnings per share in the range of $7.70 to $7.80, with the midpoint of $7.75 just under the $7.78 analyst consensus. Management said it expects non-GAAP core revenue growth to remain in the low single digits year-over-year.
Executives added that continued progress in bioprocessing and diagnostics, along with operational discipline, supported the quarter’s strong results.
